Key Takeaways
- Deal announcements on the opening day of J.P. Morgan weren’t enough to sustain investor enthusiasm through the annual business meeting.
- Investors remain concerned about big upcoming LOEs, a scarcity of financing for biotechs and uncertainty stemming from a change in presidential administration.
- Industry dealmakers said the meeting was more subdued than prior years.
The J.P. Morgan Healthcare Conference got off to a rousing start with the announcement of several deals on the first day, but the overall tone of the meeting was subdued...
Sunshine and blue skies were a pleasant change from the typical rainy J.P. Morgan backdrop, but that didn’t translate into a celebratory atmosphere on the streets around San Francisco’s Union...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?